Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis) [PDF]
Frontiers in Medicine, 2023 IntroductionBrodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family.
Luigi Gargiulo +28 more
doaj +2 more sources
Histology of psoriatic erythroderma in infants: Analytical study of eight cases
Indian Journal of Dermatology, 2015 Background: Erythroderma in infants is a rare condition of varied etiology. Psoriasis is now emerging as the most common cause of erythroderma in infants.
Parimalam Kumar +2 more
doaj +2 more sources
Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy [PDF]
Clin Drug Investig, 2017 Background and Objectives: Considering the clinical and economic burden of biological drugs in cancer treatment, it is necessary to explore how these drugs are used in routine care in Italy and how they affect the sustainability of the National Health ...
Adamo, V. (Vincenzo) +12 more
core +3 more sources
Brodalumab efficacy in psoriasis patients with inadequate response to IL-23 or IL-12/23 inhibitors: multicenter Italian retrospective analysis - IL PSO (Italian Landscape Psoriasis) [PDF]
Dermatology Practical & ConceptualIntroduction: The use of brodalumab in patients with psoriasis who have failed other biologic drugs is an under-explored topic; A variable percentage of patients still experience primary therapeutic failure, incomplete response, or progressive loss of ...
Diego Orsini +57 more
doaj +2 more sources
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) [PDF]
Frontiers in Immunology, 2023 IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients.
Luigi Gargiulo +26 more
doaj +2 more sources
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) [PDF]
Dermatology and TherapyIntroduction Guselkumab is a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA).
Mario Valenti +32 more
doaj +2 more sources
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy [PDF]
Patient Preference and Adherence, 2021 Giuseppe Argenziano,1,* Paolo Amerio,2 Maria Grazia Aragone,3 Ginevra Baggini,4 Manuela Baldari,5 Gianpiero Castelli,6 Simmaco Coppola,7 Antonio Costanzo,8,9 Rocco De Pasquale,10 Maria Concetta Fargnoli,11 Caterina Foti,12 Claudia Giofrè,13 Serena
Argenziano G +22 more
doaj +2 more sources
The Oxidative Stress‐Induced miR‐200c Is Upregulated in Psoriasis and Correlates with Disease Severity and Determinants of Cardiovascular Risk [PDF]
Oxidative Medicine and Cellular Longevity, Volume 2019, Issue 1, 2019., 2019 Psoriasis is a chronic inflammatory skin disease associated with reactive oxygen species (ROS) increase and a higher risk of cardiovascular (CV) events. We previously showed that the miR‐200 family (miR‐200s) is induced by ROS, miR‐200c being the most upregulated member responsible for apoptosis, senescence, ROS increase, and nitric oxide decrease ...
A. Magenta +13 more
wiley +2 more sources
Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK‐Targeting Drugs in Psoriasis [PDF]
Journal of Immunology Research, Volume 2018, Issue 1, 2018., 2018 IFN‐γ and IL‐22 are deeply involved in the pathogenesis of psoriasis, as they boost the expression of inflammatory genes and alter proliferative and differentiative programs in keratinocytes. The JAK1/JAK2/STAT1 and JAK1/TYK2/STAT3 pathways triggered by IFN‐γ and IL‐22, respectively, are aberrantly activated in psoriasis, as highlighted by the peculiar
Martina Morelli +8 more
wiley +2 more sources
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence [PDF]
Dermatology and TherapyPsoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to ...
Piergiorgio Malagoli +33 more
doaj +2 more sources